查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433529

先進治療藥物 CDMO 市場規模、佔有率、趨勢分析報告：按產品、階段、適應症、地區、細分市場預測，2024-2030 年

Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy), By Phase, By Indication, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

先進療法 CDMO 市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球先進療法CDMO市場規模預計將達到188億美元。

預計2024年至2030年市場複合年成長率為18.92%。這是因為先進治療藥物的臨床試驗數量不斷增加，研究人員對先進治療益處的認知不斷提高，正在推動先進治療藥物 (ATMP) CDMO 市場的成長。組織工程受益於近年來的技術發展。使用這種技術可以替代或恢復受損組織和器官的功能。同樣，基因和細胞療法正在吸引更多患者來治療全球範圍內患病率不斷上升的罕見疾病。

隨著對強大疾病治療療法的需求增加，領先公司正在專注於研究和開發在基因組層級上針對疾病原因的有效基因療法。根據ASGCT的數據，美國管道計畫（I-III期試驗）中的細胞和基因治療藥物數量從2021年的483種增加到2022年的529種。此外，FDA 持續透過多項產品製造政策支持基因治療領域的創新。 2020年1月，FDA發布了基因治療產品安全高效生產和臨床開發的六項最終指南。

此外，旨在向公眾宣傳這些產品的好處的舉措正在推動人們對 ATMP 治療方案的認知，從而增加先進治療方法的採用並刺激 CDMO 的市場成長。我正在申請。例如，細胞和基因醫學再生醫學基金會聯盟強調再生醫學的臨床和社會效益，並優先努力透過教育計畫提高公眾意識。

與新產品發布相關的臨床試驗活動的增加創造了市場成長機會。截至2022年，有1,451個ATMP處於臨床前階段，535個產品正在進行第一階段至第三階段試驗。自 2020 年 8 月以來，EMA 已額外核准了其中 6 個 ATMP，預計到 2023 年還將核准另外 5 個。在英國，2021 年約有 168 項先進治療醫學臨床試驗正在進行，比前一年的 154 項增加了 9%。 2021年一期臨床試驗增加了32%，顯示從實驗藥物到首次人體臨床試驗的重大轉變。

同時，主要企業正在採取各種策略措施來推出新產品，預計將推動市場成長。例如，2021 年 3 月，CureVac NV 與 Celonic Group 簽訂了合作夥伴協議，生產 CVnCoV，即 CureVac 的基於 mRNA 的 COVID-19 候選疫苗。 CureVac 的 COVID-19 候選疫苗將在 Celonic 位於德國海德堡的 ATMP 和生技藥品商業生產工廠生產。根據商業供應協議的條款，Celonic 的工廠將能夠生產超過 1 億劑 CVnCoV。

先進療法 CDMO 市場報告亮點：

  • 基因治療領域將佔最大佔有率，2023年將超過49.2%。資金的增加和基因治療臨床試驗數量的增加正在推動基因治療領域的需求。
  • 預計細胞治療領域將在預測期內呈現良好的成長。細胞治療領域透過整合新的細胞類型不斷發展，為公司提高市場地位提供了充足的機會。
  • 2023 年，腫瘤學領域佔銷售額的最大佔有率。該行業的主導地位是由於疾病負擔、主要企業的策略性舉措以及用於治療各種癌症適應症的先進治療方法的可用性。
  • 由於研發活動的活性化和先進療法的人體試驗數量的增加，I 期細分市場將在 2023 年佔據市場主導地位。
  • 2023年，北美以49.0%的市場佔有率主導市場。這可以歸因於外包活動的增加和對先進治療的認知的提高。
  • 由於對新型 ATMP 的需求增加以及開發新型治療方法的研發活動活性化，預計亞太地區在預測期內將以最快的複合年成長率成長。

目錄

第1章調查方法與範圍

第2章先進療法 CDMO 市場：執行摘要

  • 市場概述
  • 產品簡介
  • 階段簡介
  • 顯示簡介
  • 競爭形勢概覽

第 3 章 先進療法 CDMO 市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素分析
    • ATMP臨床試驗數量增加
    • 外包活動增加
    • 提高治療意識
  • 市場限制因素分析
    • 嚴格的監管核准
    • 外包成本高
  • 先進的治療 CDMO 市場分析工具
    • 產業分析-波特五力分析
    • PESTLE分析

第4章 先進治療藥物CDMO市場：產品預估及趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 全球先進療法 CDMO 市場（依產品前景）
  • 2018年至2030年市場規模、預測與趨勢分析如下
    • 基因治療
    • 細胞療法
    • 透過組織工程
    • 其他

第5章先進治療藥物 CDMO 市場：階段估計與趨勢分析

  • 2023年及2030年階段市場佔有率
  • 細分儀表板
  • 全球先進療法 CDMO 市場，分階段展望
  • 2018年至2030年市場規模、預測與趨勢分析如下
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段

第6章 先進治療藥物CDMO市場：適應症估計與趨勢分析

  • 2023年及2030年指示市場佔有率
  • 細分儀表板
  • 全球先進治療藥物 CDMO 市場，按適應症展望
  • 2018年至2030年市場規模、預測與趨勢分析如下
    • 腫瘤學
    • 心臟病學
    • 中樞神經系統
    • 肌肉骨骼系統
    • 感染疾病
    • 皮膚科
    • 內分泌、代謝、遺傳學
    • 免疫學和發炎
    • 眼科
    • 血液學
    • 消化內科
    • 其他

第7章 區域業務分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 西班牙
    • 法國
    • 義大利
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • List Of Key Distributors And Channel Partners
    • Key Customers
    • Key Company Market Share Analysis, 2023
    • CELONIC Group
    • Bio Elpida
    • Rentschler Biopharma SE
    • AGC Biologics
    • Catalent, Inc.
    • Lonza
    • Wuxi Advanced Therapies
    • Minaris Regenerative Medicine
    • Patheon, Inc.
    • CGT Catapult
Product Code: GVR-4-68039-676-6

Advanced Therapy Medicinal Products CDMO Market Growth & Trends:

The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.92% from 2024 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth. Tissue engineering has greatly benefited in recent years from technological development. The damaged tissues and organ function are replaced or restored using this technique. Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.

With rising demand for robust disease treatment therapies, key players have focused their efforts to ramp up research and development for effective gene therapies that target the cause of disorder at a genomic level. According to ASGCT, the number of cell and gene therapies in the U.S. pipeline programs (phase I-III trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA delivers constant support for innovations in the gene therapy field via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.

Moreover, awareness about ATMP treatment options is being driven by initiatives aimed at informing the public about the benefits of these products, which, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine prioritizes activities for increasing public awareness through educational programs, underlining the clinical & societal benefits of regenerative medicine.

Increasing clinical trial activity along with new product launches generates growth opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved six of these additional ATMPs, and five more will be approved by 2023. In the UK, there were approximately 168 advanced therapy medicinal product trials underway in 2021, up from the 154 studies reported the year before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a significant shift from experimental medicines to first-in-human studies.

On the other hand, key players are undertaking various strategic initiatives to introduce novel products, which is expected to propel market growth. For instance, in March 2021, CureVac N.V. signed a partnership agreement with Celonic Group, engaged in the manufacture of CVnCoV, CureVac's mRNA-based COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics in Heidelberg, Germany. Under the terms of the commercial supply agreement, the Celonic facility could produce over 100 million doses of CVnCoV.

Advanced Therapy Medicinal Products CDMO Market Report Highlights:

  • The gene therapy segment held the largest share of over 49.2% in 2023. Increase in financial support and rise in number of clinical trials for gene therapies are driving demand for the gene therapy segment.
  • The cell therapy segment is expected to show lucrative growth over the forecast period. The field of cellular therapeutics is constantly advancing with inclusion of new cell types, which, in turn, provides ample opportunities for companies to enhance their market positions.
  • The oncology segment accounted for the largest revenue share in 2023. The segment's dominance is attributed to disease burden, strategic initiatives undertaken by key players, and availability of advanced therapies used for treating various cancer indications.
  • The phase I segment dominated the market in 2023 due to growing R&D activities and increasing number of human trials for advanced therapies.
  • North America dominated the overall market share of 49.0% in 2023. This can be attributed to increasing outsourcing activities and rising awareness about advanced therapy.
  • The Asia Pacific region is expected to grow at the fastest CAGR over the forecast period due to the increasing demand for novel ATMPs and rising R&D activities to develop novel therapies.

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation And Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Phase Segment
      • 1.1.1.3. Indication Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List Of Primary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Advanced Therapy Medicinal Products CDMO Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Products Snapshots
  • 2.3. Phase Snapshots
  • 2.4. Indication Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Advanced Therapy Medicinal Products CDMO Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising number of clinical trials for ATMPs
    • 3.4.2. Increasing outsourcing activities
    • 3.4.3. Growing awareness of the treatment
  • 3.5. Market Restraint Analysis
    • 3.5.1. Stringent regulatory approvals
    • 3.5.2. High cost of outsourcing
  • 3.6. Advanced Therapy Medicinal Products CDMO Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat Of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape

Chapter 4. Advanced Therapy Medicinal Products CDMO: Products Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Advanced Therapy Medicinal Products CDMO Market, By Product Outlook
  • 4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 4.4.1. Gene Therapy
      • 4.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.2. Cell Therapy
      • 4.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.3. Tissue Engineered
      • 4.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 5. Advanced Therapy Medicinal Products CDMO: Phase Estimates & Trend Analysis

  • 5.1. Phase Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Advanced Therapy Medicinal Products CDMO Market, By Phase Outlook
  • 5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 5.4.1. Phase I
      • 5.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.2. Phase II
      • 5.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.3. Phase III
      • 5.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 5.4.4. Phase IV
      • 5.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 6. Advanced Therapy Medicinal Products CDMO: Indication Estimates & Trend Analysis

  • 6.1. Indication Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Advanced Therapy Medicinal Products CDMO Market, By Indication Outlook
  • 6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.2. Cardiology
      • 6.4.2.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.3. Central Nervous System
      • 6.4.3.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.4. Musculoskeletal
      • 6.4.4.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.5. Infectious Disease
      • 6.4.5.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.6. Dermatology
      • 6.4.6.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.7. Endocrine, Metabolic, Genetic
      • 6.4.7.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.8. Immunology & Inflammation
      • 6.4.8.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.9. Ophthalmology
      • 6.4.9.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.10. Hematology
      • 6.4.10.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.11. Gastroenterology
      • 6.4.11.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 6.4.12. Others
      • 6.4.12.1. Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. U.S. Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Canada Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. UK Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Germany Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.3. Spain
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Spain Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. France Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Italy Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.6. Denmark
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Denmark Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Sweden Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.6.8. Norway
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Framework
      • 7.6.8.4. Norway Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Japan Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. China Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. India Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.4. South Korea
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. South Korea Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.5. Thailand
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Thailand Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.7.6. Australia
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Australia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. Brazil Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Mexico Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Argentina Market Estimates And Forecasts, 2018 To 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA Advanced Therapy Medicinal Products CDMO Market, 2018 - 2030 (USD Million)
    • 7.9.2. South Africa
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. South Africa Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Saudi Arabia Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key Country Dynamics
      • 7.9.4.2. Competitive Scenario
      • 7.9.4.3. Regulatory Framework
      • 7.9.4.4. UAE Market Estimates And Forecasts, 2018 To 2030 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key Country Dynamics
      • 7.9.5.2. Competitive Scenario
      • 7.9.5.3. Regulatory Framework
      • 7.9.5.4. Kuwait Market Estimates And Forecasts, 2018 To 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company /Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List Of Key Distributors And Channel Partners
    • 8.3.2. Key Customers
    • 8.3.3. Key Company Market Share Analysis, 2023
    • 8.3.4. CELONIC Group
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Bio Elpida
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Rentschler Biopharma SE
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. AGC Biologics
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Catalent, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Lonza
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Wuxi Advanced Therapies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Minaris Regenerative Medicine
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Patheon, Inc.
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. CGT Catapult
      • 8.3.13.1. Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Product Benchmarking
      • 8.3.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 3 North America Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 4 North America Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 5 North America Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 7 U.S. Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 8 U.S. Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 9 Canada Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 10 Canada Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 11 Canada Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 13 Europe Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 14 Europe Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Europe Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 16 UK Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 17 UK Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 18 UK Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 19 Germany Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 20 Germany Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 21 Germany Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 22 France Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 23 France Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 France Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 25 Italy Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Italy Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 27 Italy Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 28 Spain Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 29 Spain Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Spain Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 31 Sweden Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 32 Sweden Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Sweden Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 34 Norway Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 35 Norway Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Norway Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 37 Denmark Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 38 Denmark Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Denmark Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 44 Japan Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 Japan Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 46 Japan Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 47 China Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 China Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 49 China Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 50 India Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 India Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 52 India Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 53 Australia Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 Australia Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 55 Australia Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 56 South Korea Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 57 South Korea Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 58 South Korea Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 59 Thailand Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Thailand Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 61 Thailand Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 62 Latin America Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 64 Latin America Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 65 Latin America Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 66 Brazil Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 67 Brazil Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 68 Brazil Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 69 Argentina Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 70 Argentina Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 71 Argentina Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 72 Mexico Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 73 Mexico Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 74 Mexico Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 75 MEA Advanced Therapy Medicinal Products CDMO Market, by Region, 2018 - 2030 (USD Million)
  • Table 76 MEA Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 77 MEA Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 78 MEA Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 79 South Africa Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 80 South Africa Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 81 South Africa Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 85 UAE Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 86 UAE Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 87 UAE Advanced Therapy Medicinal Products CDMO Market, Indication, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Advanced Therapy Medicinal Products CDMO Market, by Product, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Advanced Therapy Medicinal Products CDMO Market, by Phase, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Advanced Therapy Medicinal Products CDMO Market, Test type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews In North America
  • Fig. 5 Primary Interviews In Europe
  • Fig. 6 Primary Interviews In Asia Pacific
  • Fig. 7 Primary Interviews In Latin America
  • Fig. 8 Primary Interviews In Middle East & Africa
  • Fig. 9 Market Research Approaches
  • Fig. 10 Value-Chain-Based Sizing & Forecasting
  • Fig. 11 QFD Modeling For Market Share Assessment
  • Fig. 12 Market Formulation & Validation
  • Fig. 13 Advanced Therapy Medicinal Products CDMO Market: Market Outlook
  • Fig. 14 Advanced Therapy Medicinal Products CDMO Competitive Insights
  • Fig. 15 Parent Market Outlook
  • Fig. 16 Related/Ancillary Market Outlook
  • Fig. 17 Penetration And Growth Prospect Mapping
  • Fig. 18 Industry Value Chain Analysis
  • Fig. 19 Advanced Therapy Medicinal Products CDMO Market Driver Impact
  • Fig. 20 Advanced Therapy Medicinal Products CDMO Market Restraint Impact
  • Fig. 21 Advanced Therapy Medicinal Products CDMO Market Strategic Initiatives Analysis
  • Fig. 22 Advanced Therapy Medicinal Products CDMO Market: Product Movement Analysis
  • Fig. 23 Advanced Therapy Medicinal Products CDMO Market: Product Outlook And Key Takeaways
  • Fig. 24 Gene Therapy Market Estimates And Forecast, 2018 - 2030
  • Fig. 25 Cell Therapy Estimates And Forecast, 2018 - 2030
  • Fig. 26 Tissue Engineered Estimates And Forecast, 2018 - 2030
  • Fig. 27 Others Estimates And Forecast, 2018 - 2030
  • Fig. 28 Advanced Therapy Medicinal Products CDMO Market: Phase Movement Analysis
  • Fig. 29 Advanced Therapy Medicinal Products CDMO Market: Phase Outlook And Key Takeaways
  • Fig. 30 Phase I Market Estimates And Forecasts, 2018 - 2030
  • Fig. 31 Phase II Market Estimates And Forecasts, 2018 - 2030
  • Fig. 32 Phase III Market Estimates And Forecasts, 2018 - 2030
  • Fig. 33 Phase IV Market Estimates And Forecasts, 2018 - 2030
  • Fig. 34 Advanced Therapy Medicinal Products CDMO Market: Indication Movement Analysis
  • Fig. 35 Advanced Therapy Medicinal Products CDMO Market: Indication Outlook And Key Takeaways
  • Fig. 36 Oncology Market Estimates And Forecasts, 2018 - 2030
  • Fig. 37 Cardiology Market Estimates And Forecasts,2018 - 2030
  • Fig. 38 Central Nervous System Estimates And Forecasts, 2018 - 2030
  • Fig. 39 Musculoskeletal Estimates And Forecasts, 2018 - 2030
  • Fig. 40 Infectious Disease Estimates And Forecasts, 2018 - 2030
  • Fig. 41 Dermatology Estimates And Forecasts, 2018 - 2030
  • Fig. 42 Others Estimates And Forecasts, 2018 - 2030
  • Fig. 43 Global Advanced Therapy Medicinal Products CDMO Market: Regional Movement Analysis
  • Fig. 44 Global Advanced Therapy Medicinal Products CDMO Market: Regional Outlook And Key Takeaways
  • Fig. 45 Global Advanced Therapy Medicinal Products CDMO Market Share And Leading Players
  • Fig. 46 North America Market Share And Leading Players
  • Fig. 47 Europe Market Share And Leading Players
  • Fig. 48 Asia Pacific Market Share And Leading Players
  • Fig. 49 Latin America Market Share And Leading Players
  • Fig. 50 Middle East & Africa Market Share And Leading Players
  • Fig. 51 North America: SWOT
  • Fig. 52 Europe SWOT
  • Fig. 53 Asia Pacific SWOT
  • Fig. 54 Latin America SWOT
  • Fig. 55 MEA SWOT
  • Fig. 56 North America
  • Fig. 57 North America Market Estimates And Forecasts, 2018 - 2030
  • Fig. 58 U.S.
  • Fig. 59 U.S. Market Estimates And Forecasts, 2018 - 2030
  • Fig. 60 Canada
  • Fig. 61 Canada Market Estimates And Forecasts, 2018 - 2030
  • Fig. 62 Europe
  • Fig. 63 Europe Market Estimates And Forecasts, 2018 - 2030
  • Fig. 64 UK
  • Fig. 65 UK Market Estimates And Forecasts, 2018 - 2030
  • Fig. 66 Germany
  • Fig. 67 Germany Market Estimates And Forecasts, 2018 - 2030
  • Fig. 68 France
  • Fig. 69 France Market Estimates And Forecasts, 2018 - 2030
  • Fig. 70 Italy
  • Fig. 71 Italy Market Estimates And Forecasts, 2018 - 2030
  • Fig. 72 Spain
  • Fig. 73 Spain Market Estimates And Forecasts, 2018 - 2030
  • Fig. 74 Denmark
  • Fig. 75 Denmark Market Estimates And Forecasts, 2018 - 2030
  • Fig. 76 Sweden
  • Fig. 77 Sweden Market Estimates And Forecasts, 2018 - 2030
  • Fig. 78 Norway
  • Fig. 79 Norway Market Estimates And Forecasts, 2018 - 2030
  • Fig. 80 Asia Pacific
  • Fig. 81 Asia Pacific Market Estimates And Forecasts, 2018 - 2030
  • Fig. 82 China
  • Fig. 83 China Market Estimates And Forecasts, 2018 - 2030
  • Fig. 84 Japan
  • Fig. 85 Japan Market Estimates And Forecasts, 2018 - 2030
  • Fig. 86 India
  • Fig. 87 India Market Estimates And Forecasts, 2018 - 2030
  • Fig. 88 Thailand
  • Fig. 89 Thailand Market Estimates And Forecasts, 2018 - 2030
  • Fig. 90 South Korea
  • Fig. 91 South Korea Market Estimates And Forecasts, 2018 - 2030
  • Fig. 92 Australia
  • Fig. 93 Australia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 94 Latin America
  • Fig. 95 Latin America Market Estimates And Forecasts, 2018 - 2030
  • Fig. 96 Brazil
  • Fig. 97 Brazil Market Estimates And Forecasts, 2018 - 2030
  • Fig. 98 Mexico
  • Fig. 99 Mexico Market Estimates And Forecasts, 2018 - 2030
  • Fig. 100 Argentina
  • Fig. 101 Argentina Market Estimates And Forecasts, 2018 - 2030
  • Fig. 102 Middle East And Africa
  • Fig. 103 Middle East And Africa Market Estimates And Forecasts, 2018 - 2030
  • Fig. 104 South Africa
  • Fig. 105 South Africa Market Estimates And Forecasts, 2018 - 2030
  • Fig. 106 Saudi Arabia
  • Fig. 107 Saudi Arabia Market Estimates And Forecasts, 2018 - 2030
  • Fig. 108 UAE
  • Fig. 109 UAE Market Estimates And Forecasts, 2018 - 2030
  • Fig. 110 Kuwait
  • Fig. 111 Kuwait Market Estimates And Forecasts, 2018 - 2030
  • Fig. 112 Market Share Of Key Market Players - Advanced Therapy Medicinal Products CDMO Market